Droperidol
FDA-approved product (injectable, injection), marketed as Droperidol, Inapsine.
- Registered studies
- 42
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Nausea and vomiting
- Post operative nausea and vomiting
- Psychosis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Butyrophenone derivatives
- FDA pharmacologic class
- Dopamine-2 Receptor Antagonist FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA48.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli43.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae32.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis55.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
42registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Droperidol with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Ozanimod HydrochlorideExisting use: Multiple sclerosis, Relapsing-remitting multiple sclerosis, Ulcerative colitis66.8% AI-predicted activityagainst MRSA7 registered studies
- Micafungin SodiumExisting use: Candidiasis66.8% AI-predicted activityagainst MRSA50+ registered studies
- AbemaciclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more66.4% AI-predicted activityagainst MRSA50+ registered studies
- RisperidoneExisting use: Aggressive behavior, Autism, Bipolar disorder and 4 more66.4% AI-predicted activityagainst MRSA50+ registered studies
- Lazertinib MesylateExisting use: Non-small cell lung carcinoma66.1% AI-predicted activityagainst MRSANo documented evidence found
- Desmopressin AcetateExisting use: Central diabetes insipidus, Diabetes insipidus, Enuresis and 5 more65.8% AI-predicted activityagainst MRSA50+ registered studies
- Terazosin HydrochlorideExisting use: Benign prostatic hyperplasia65.8% AI-predicted activityagainst MRSA41 registered studies
- VemurafenibExisting use: Cancer, Cutaneous melanoma, Melanoma and 2 more65.8% AI-predicted activityagainst MRSA50+ registered studies
- Caspofungin AcetateExisting use: Aspergillosis, Candidemia, Candidiasis and 1 more65.5% AI-predicted activityagainst MRSA50+ registered studies
- VenetoclaxExisting use: Cancer, Chronic lymphocytic leukemia, Neoplasm65.5% AI-predicted activityagainst MRSA50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more65.4% AI-predicted activityagainst MRSA5 registered studies
- SirolimusExisting use: Adenoma sebaceum, Angiofibroma, Cancer and 5 more65.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Drug Interactions Between Paracetamol and Setrons in Pain Management
NCT01432977 · start 2011-09
Registered record
- Registry ID
- NCT01432977
- Conditions
- Pain
- Interventions
- paracetamol /droperidol; paracetamol / ondansetron
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2011-09
- Completion
- 2012-06
- Enrolment
- 72
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPainInterventionparacetamol /droperidol; paracetamol / ondansetronPhasePhase 3Registry statusCompletedDroperidol Versus Metoclopramide + Diphenhydramine for the Treatment of Primary Headaches
NCT01406860 · start 2011-07
Registered record
- Registry ID
- NCT01406860
- Conditions
- Primary Headaches (Includes Migraines, Tension, Cluster Headaches)
- Interventions
- Droperidol; Metoclopramide + diphenhydramine
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Terminated
- Start
- 2011-07
- Completion
- 2012-07
- Enrolment
- 19
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPrimary Headaches (Includes Migraines, Tension, Cluster Headaches)InterventionDroperidol; Metoclopramide + diphenhydraminePhaseNot applicableRegistry statusTerminatedDroperidol and Cardiac Repolarization
NCT01819857 · start 2011-06
Registered record
- Registry ID
- NCT01819857
- Conditions
- Cardiac Repolarization
- Interventions
- Xomolix 0.625 mg intravenously; Xomolix 1.25 mg; Zofran 8 mg
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2011-06
- Completion
- 2013-07
- Enrolment
- 75
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCardiac RepolarizationInterventionXomolix 0.625 mg intravenously; Xomolix 1.25 mg; Zofran 8 mgPhasePhase 4Registry statusCompletedIncidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.
NCT01298193 · start 2011-05
Registered record
- Registry ID
- NCT01298193
- Conditions
- Breast Cancer
- Interventions
- Aprepitant
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2011-05
- Completion
- 2014-04
- Enrolment
- 212
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast CancerInterventionAprepitantPhasePhase 4Registry statusCompletedEnhanced Recovery After Laparoscopic Sleeve Gastrectomy - a Randomised Controlled Trial
NCT01303809 · start 2011-05
Registered record
- Registry ID
- NCT01303809
- Conditions
- Morbid Obesity
- Interventions
- Enhanced Recovery After Surgey for Sleeve Gastrectomy
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2011-05
- Completion
- 2012-05
- Enrolment
- 106
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMorbid ObesityInterventionEnhanced Recovery After Surgey for Sleeve GastrectomyPhaseNot applicableRegistry statusCompletedPostoperative Vomiting in Children: Comparison Tri - Versus bi -Prophylaxis
NCT01739985 · start 2010-12
Registered record
- Registry ID
- NCT01739985
- Conditions
- Postoperative Vomiting
- Interventions
- Dexamethasone + ondansetron + Placebo; Dexamethasone + ondansetron + Droperidol
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2010-12
- Completion
- 2014-05
- Enrolment
- 322
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostoperative VomitingInterventionDexamethasone + ondansetron + Placebo; Dexamethasone + ondansetron + DroperidolPhaseNot applicableRegistry statusCompletedAntagonism Research Between Antiemetics Agents and Acetaminophen in Thyroidectomy's Post-operative Analgesia.
NCT01679093 · start 2009-06
Registered record
- Registry ID
- NCT01679093
- Conditions
- Interaction Between Antiemetic Drugs and Paracetamol
- Interventions
- ondansetron; Droperidol; Dexamethasone
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2009-06
- Completion
- 2011-06
- Enrolment
- 66
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInteraction Between Antiemetic Drugs and ParacetamolInterventionondansetron; Droperidol; DexamethasonePhasePhase 3Registry statusCompletedComparison of Three Different Prophylactic Treatments of Postoperative Nausea and Vomiting (PONV) in Children
NCT01434017 · start 2008-11
Registered record
- Registry ID
- NCT01434017
- Conditions
- Postoperative Nausea and Vomiting
- Interventions
- Dexamethasone; Dexamethasone and droperidol; Dexamethasone and Ondansetron
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2008-11
- Completion
- 2013-06
- Enrolment
- 300
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostoperative Nausea and VomitingInterventionDexamethasone; Dexamethasone and droperidol; Dexamethasone and OndansetronPhasePhase 4Registry statusCompletedRole of Droperidol in Postoperative Vomiting
NCT00702442 · start 2008-06
Registered record
- Registry ID
- NCT00702442
- Conditions
- Vomiting
- Interventions
- Droperidol; Saline solution
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2008-06
- Completion
- 2011-07
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionVomitingInterventionDroperidol; Saline solutionPhasePhase 4Registry statusCompletedThe Effects of the Anti Nausea Drugs Droperidol and Ondansetron on the Way the Heart Recovers Between Beats
NCT00624208 · start 2008-02
Registered record
- Registry ID
- NCT00624208
- Conditions
- Myocardial Repolarization
- Interventions
- droperidol and saline; ondansetron and saline; droperidol and ondansetron; saline and saline
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2008-02
- Completion
- 2009-08
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMyocardial RepolarizationInterventiondroperidol and saline; ondansetron and saline; droperidol and ondansetron; saline and salinePhaseNot applicableRegistry statusCompletedEvaluation of 2 Doses of Intravenous Droperidol in the Prevention of Postoperative Nausea
NCT00445055 · start 2007-04
Registered record
- Registry ID
- NCT00445055
- Conditions
- Nausea; Vomiting
- Interventions
- Droperidol
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Terminated
- Start
- 2007-04
- Completion
- 2009-04
- Enrolment
- 71
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNausea; VomitingInterventionDroperidolPhasePhase 4Registry statusTerminatedOptimal Multimodal Analgesia in Laparoscopic Cholecystectomy
NCT00209885 · start 2005-10
Registered record
- Registry ID
- NCT00209885
- Conditions
- Cholecystolithiasis
- Interventions
- Gabapentin; S-ketamine; Lidocaine; Droperidol
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2005-10
- Completion
- Not recorded
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCholecystolithiasisInterventionGabapentin; S-ketamine; Lidocaine; DroperidolPhasePhase 4Registry statusUnknown